Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice
1996

Using LDL to Target Cancer Cells

Sample size: 10 publication Evidence: moderate

Author Information

Author(s): AJ Versluis, PJ van Geel, H Oppelaar, TJC van Berkell, MK Bijsterbosch

Primary Institution: Leiden/Amsterdam Center for Drug Research, University of Leiden; The Netherlands Cancer Institute

Hypothesis

Can low-density lipoprotein (LDL) be used as a carrier for selective delivery of anti-neoplastic drugs to tumors?

Conclusion

The study concludes that B16 tumor-bearing mice are a suitable model for evaluating LDL-mediated delivery of cytotoxic drugs to tumors.

Supporting Evidence

  • B16 melanoma cells bind LDL with high affinity, indicating potential for drug delivery.
  • LDL uptake by B16 tumors was higher than in other tissues, suggesting selective targeting.
  • Receptor-mediated uptake of LDL can be regulated by the cholesterol needs of the cells.

Takeaway

This study shows that LDL can help deliver cancer-fighting drugs directly to tumors, which could reduce side effects.

Methodology

The study involved in vitro experiments with B16 melanoma cells and in vivo experiments with C57/BL6 mice to evaluate LDL uptake.

Limitations

The study's findings may not directly translate to human tumors due to differences in LDL receptor expression.

Participant Demographics

Male C57/BL6 mice, 10-15 weeks old.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication